You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 561 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
561 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021264012
Dec 20215206
Jan 20222805
Feb 20221805
Mar 202213405
Apr 20225004
May 202230015
Jun 20225008
Jul 20222003
Aug 20222401
Sep 20222609
Oct 20221804
Nov 20222005
Dec 20222800
Jan 20232004
Feb 20232803
Mar 20232201
Apr 2023602
May 2023802
Jun 2023201
Jul 20231208
Aug 20231405
Sep 20231001
Oct 20231002
Nov 20232603
Dec 20231601
Jan 20242203
Feb 20241402
Mar 20241601
Apr 20241601
May 20241000
Jun 20241802
Jul 20241204
Aug 20241403
Sep 20241403
Total10720134